Cocrystal Pharma discusses clinical progress and significance of its new antiviral therapeutic pipeline with The Stock Day podcast

Receive instant alerts when news about your stock arrives. Claim your free 1 week trial at Street Insider Premium here.

Phoenix, Arizona–(Newsfile Corp. – January 23, 2023) – The Stock Day podcast welcomed Cocrystal Pharma, Inc. (NASDAQ: COCP) (“Cocrystal”, “Cocrystal Pharma” or “the Company”), a clinical-biotechnology company in the discovery and development phase of novel antiviral therapies targeting the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C virus and noroviruses. Cocrystal employs unique technologies based on Nobel Prize-winning structure and expertise to create world-class, best-in-class antiviral drugs. Company co-CEO and CFO Jim Martin joined Stock Day host Everett Jolly.

Jolly began the interview by asking about the company’s background and current projects. “Cocrystal is an antiviral therapeutic company,” Martin shared. “As distinct from a vaccine company, we seek to provide a solution to treat patients when they fall ill,” he continued. “We have several areas we work on, including influenza, COVID-19 and norovirus,” Martin said. “We also have a drug discovery platform derived from the founders, one of whom received a Nobel Prize for antiviral therapies and industrialized it into what became Cocrystal.”

“Could you provide us with an update on Cocrystal Pharma’s Phase 1 Influenza A study?” Jolly asked. “The flu is a multibillion-dollar problem,” Martin said. “What we have is an antiviral, oral therapeutic that’s being developed as a once-a-day pill,” he said. “We have just completed a Phase 1 clinical trial in Australia,” Martin shared, adding that the trial yielded encouraging results and Cocrystal Pharma will move to a Phase 2a trial in the UK. “We will conduct the process this year and conclude by the end of the year.”

“Could you also provide an update on Cocrystal Pharma’s COVID-19 clinical candidate?” Jolly asked. “With COVID-19, there is currently no approved therapy,” Martin explained. “We’re going into a clinical trial this year in Australia,” he shared. “We have a great team to run this process and we’re starting this quarter.”

Jolly then inquired about the company’s current financial condition, as well as its capital needs for the future. “We are well capitalized with a very strong balance sheet, which really sets us apart from many biotech companies,” Martin said. “We have no debt on the balance sheet,” he added. “We are in a uniquely strong position, along with our pipeline to drive us forward and add value to our shareholders.”

“What makes Cocrystal Pharma special?” Jolly asked. “We are an antiviral company with multi-billion dollar claims in influenza, COVID-19 and norovirus,” Martin shared. “We have progressed clinically on these assets,” he added. “We are well prepared for the future with both capital and our position with the Nasdaq, as well as having zero debt and zero warrants on our balance sheet,” said Martin, before delving into the Company’s wealth of expertise through their advisory board and team management.

To conclude the interview, Martin encouraged listeners and shareholders to stay abreast of the company’s current and future plans as they continue to clinically advance their antiviral assets in a high-demand market.

To hear Jim Martin’s full interview, follow the podcast link here: -therapeutics .

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapies targeting the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C virus, and noroviruses. Cocrystal employs unique technologies based on Nobel Prize-winning structure and expertise to create world-class, best-in-class antiviral drugs. For more information about Cocrystal, visit

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements pursuant to the Private Securities Litigation Reform Act of 1995, including statements relating to the progress of Cocrystal’s clinical programs, including Phase 1 study results for its influenza A drug candidate and progression towards a Phase 2a study in the UK, the anticipated COVID-19 trial, the market and demand for in-development product candidates, and liquidity. The words “believe”, “may”, “estimate”, “continue”, “anticipate”, “intend”, “should”, “plan”, “could”, “target”, “potential”, “is likely, ” “will,” “expect” and similar expressions, as they refer to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated in these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, risks and uncertainties arising from any future impact of COVID-19 and its current spread in China and potential spread to the US and other places where clinical trials are conducted for our studies, inflation, interest rate hikes and war in Ukraine against the UK and the global economy and against our company, including supply chain disruptions and our continued ability to proceed with our programs, including our influenza A program, the contract research organization’s ability to recruit patients into clinical trials, the results of future preclinical and clinical studies, and the overall risks arising from clinical trials. Additional information about our risk factors is contained in our SEC filings, including our annual report on Form 10-K for the year ended December 31, 2021. Any forward-looking statements made by us herein speak only as of the date in which it is made. From time to time factors or events may arise that could cause our actual results to differ, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

Investor contact:
LHA Investor Relations
Jody Cain
[email protected]

Media contact:
JQA Partners
Julius Abraham
[email protected]

About the “Stock Day” Podcast.

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. Educate investors while working with penny stocks and OTC companies simultaneously, providing transparency and insight into the market’s undervalued and undersold Micro-Cap stocks. Stock Day provides companies with customized solutions for their news distribution in national and international media. The Stock Day Podcast is the number one radio show of its kind in America.

Trading day average
(602) 821-1102

To view the original version of this news release, please visit

Add a Comment

Your email address will not be published. Required fields are marked *